Pharming Gains FDA Priority Review for Lower-Dose Joenja
LEIDEN, Netherlands — September 25, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LEIDEN, Netherlands — September 25, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
LEIDEN, Netherlands — September 11, 2026 Pharming Group N.V. announced that the U.S. Food and Drug Administration (FDA) has...
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
Leiden, Netherlands, May 22, 2026 Pharming Group N.V. has announced that the European Commission (EC) has granted Marketing Authorization...
Leiden, the Netherlands, May 7, 2026 Pharming Group N.V. announced a major scientific presence at the 2026 Annual Meeting...
LEIDEN, Netherlands, March 27, 2026 Pharming Group N.V. announced that the Committee for Medicinal Products for Human Use (CHMP)...
LEIDEN, NETHERLANDS, March 24, 2026 Pharming Group has announced that Japan’s Ministry of Health, Labour and Welfare has approved...
LEIDEN, Netherlands, Feb. 1, 2026 — Pharming Group announced that the U.S. Food and Drug Administration (FDA) has issued...
